R. et al. Telisotuzumab vedotin monotherapy in patients with previously treated c-Met–overexpressing non-squamous EGFR wildtype advanced NSCLC: primary analysis of the LUMINOSITY trial. J. Clin. Oncol. 42, 103–103 (2024). Article Google Scholar Passaro, A., Jänne, P. A. & Peters,...
We present a comprehensive ancestry-based prevalence and co-alteration landscape of genomic alterations and immunotherapy-associated biomarkers in patients withand-altered non-squamous (non-Sq) NSCLC.was the most frequently altered oncogene in European (EUR) and African (AFR), whilealterations ...
EP: 1.ADAURA: Overall Survival Analysis of Osimertinib in NSCLC Now Viewing EP: 2.KEYNOTE-789: Chemotherapy With or Without Pembrolizumab for TKI-Resistant Nonsquamous NSCLC EP: 3.KEYNOTE-671: Perioperative Use of Pembrolizumab in Early-Stage NSCLC ...
et al. Long-term overall survival from KEYNOTE-021 cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous NSCLC. J. Thorac. Oncol. 16, 162–168 (2021). Article CAS PubMed Google Scholar Paz-Ares, L. et al. A randomized, ...
Moreover, the MET status in non-squamous NSCLC tumor areas showed highly heterogeneous among various histotypes, hindering the adequate patient selection for MET-targeted therapies[12]. The intratumor heterogeneity referred to subclonal diversities of tumor cells was observed in this study. The ...
(NSCLC) is a heterogeneous class of tumors consisting of two major histologic subtypes:adenocarcinomaandsquamous cellcarcinoma (Rafei et al., 2017). The main risk factor for the development of NSCLC is tobacco smoke, yet inhalation of other carcinogens and exposure to radon, asbestos,diesel ...
To describe cost-effectiveness of pembrolizumab plus platinum and pemetrexed chemotherapy in metastatic, non-squamous, NSCLC patients in the US.A model is developed utilizing partitioned survival analysis to estimate the cost-effectiveness of KEYNOTE-189 trial comparators pembrolizumab+chemotherapy (carboplat...
Squamous cell carcinoma Large-cell carcinoma Like all cancers, lung cancer is most easily and successfully treated if it is caught early. An early-stage cancer is less likely to have grown to a large size or to have spread to other parts of the body (metastasized). Large or metastasized ca...
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer.What are the subtypes of NSCLC?Squamous cell carcinoma is found in cells that line the airways of the lungs. It is usually found in the middle of the lung. Adenocarcinoma is found in cells that produce mucus. It...
Non-small-cell lung cancer (NSCLC) is the most common type of cancer affecting the lungs. The diverse types of NSCLC are characterized by cancer cells that grow and spread in different ways. The three most common forms of NSCLC are adenocarcinoma, squamous cell carcinoma and large cell carcino...